Abstract
Continued tumor growth is dependent upon the growth of new blood vessels. This commentary reviews the mechanisms whereby tumors become vascularized and examines whether tumor angiogenesis is solely an example of a normal physiologic process or is part of the genetic program of the tumor. The likelihood that neovascularization of tumors combines both of these components, that is, utilizing tumor-specific elements as well as capacities common to all cells, is discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409–416, 1972
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo Nature 362: 841–844, 1993
Millauer B, Shawver LK, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576–579, 1994
Warren RS, Yuan H, Matli MR, Gillett N, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789–1797, 1995
Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15: 4738–4747, 1995
Hudlicka O: Development and adaptability of microvasculature in skeletal muscle. J Exp Biol 115: 215–228, 1985
Hudlicka O, Brown M, Egginton S: Angiogenesis in skeletal and cardiac muscle. Physiol Rev 72: 369–417, 1992
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845, 1992
Shima DT, Adamis AP, Yeo K-T, Yeo T-K, Allende R, Folkman J, D'Amore PA: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1: 182–193, 1995
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848, 1992
Shweiki D, Neeman M, Itin A, Keshet E: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implication for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768–772, 1995
Dvorak H, Brown L, Detmar M, Dvorak A: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Path 146: 1029–1038, 1995
Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92: 905–909, 1995
Adarnis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW: Inhibition of VEGF prevents ocular neovascularization in a primate. Arch Ophthalmol 114: 66–71, 1996
Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, et al.: Vascular permeability factor/vascular endothelial cell growth factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574–584, 1994
D'Amore PA: Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 6: 1–8, 1992
Folkman J: Angiogenesis inhibitors generated by tumors. Mol Med 1: 120–122, 1996
Christofori G, Hanahan D: Molecular dissection of multistage tumorigenesis in transgenic mice. Semin Cancer Biol 5: 3–21, 1994
Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66: 1095–1104, 1991
Dietrich WF, Radany EH, Smith JS, Bishop JM, Hanahan D, Lander ES: Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc Natl Acad Sci USA 91: 9451–9455, 1994
Rastinejad F, Polverini PJ, Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56: 345–355, 1989
Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87: 6624–6628, 1990
Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582–1584, 1994
RayChaudhury A, Frazier WA, D'Amore PA: Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta. J Cell Sci 107: 39–46, 1994
Sheibani N, Frazier WA: Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 92: 6788–6792, 1995
Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Met Rev 14: 263–277, 1995
Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D: Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cell. J Biol Chem 270: 25915–25919, 1995
Rak J, Bayko L, Filmus J, Shirasawa S, Kerber RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575–4580, 1995
Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo K-T, Manseau EL, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172–196, 1996
Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149–153, 1995
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1: 27–31, 1995
Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA: An activated form of TGF-β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86: 4544–4548, 1989
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 315–328, 1994
Lu C, Kerbel RS: Cytokines, growth factors and the loss of negative growth control in the progression of human cutaneous malignant melanoma. Curr Opin Oncol 6: 212–220, 1994
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giacca AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88–90, 1996
Kinzler KW, Vogelstein B: Life (and death) in a malignant tumor. Nature 73: 19–20, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
D'Amore, P.A., Shima, D.T. Tumor angiogenesis: A physiological process or genetically determined?. Cancer Metast Rev 15, 205–212 (1996). https://doi.org/10.1007/BF00437473
Issue Date:
DOI: https://doi.org/10.1007/BF00437473